New opioid side effects and implications for long-term therapy

Trends in Anaesthesia and Critical Care

Volumn 1, Issue 1, 2011, Pages 18-21

  Raghavan, S ^a   Harvey, A D ^b   Humble, S R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cognitive impairment; Drug side effects; Hyperalgesia; Hypogonadism; Immune suppression; Opioids

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; ANTICONVULSIVE AGENT; BUPRENORPHINE; DEXTROPROPOXYPHENE; DIZOCILPINE; FENTANYL; HYDROMORPHONE; LUTEINIZING HORMONE; MORPHINE; OPIATE; OXYCODONE; PETHIDINE; PRASTERONE; TESTOSTERONE; TRAMADOL;

ADDICTION; AMENORRHEA; CANCER PAIN; CHRONIC DISEASE; CHRONIC PAIN; COGNITIVE DEFECT; CONSTIPATION; DYSMENORRHEA; EMERGENCY TREATMENT; FRACTURE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERALGESIA; HYPOGONADISM; IMMUNOSUPPRESSIVE TREATMENT; LIBIDO; LONG TERM CARE; LUTEINIZING HORMONE BLOOD LEVEL; MORBIDITY; NAUSEA; NONHUMAN; OSTEOPOROSIS; PAIN; PHYSICIAN; PRIORITY JOURNAL; REVIEW; TESTOSTERONE BLOOD LEVEL;

EID: 79952739048     PISSN: 22108440     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cacc.2010.06.003     Document Type: Review

References (40)

1. Rajagopal A, Vassilopoulo-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to morphine. Cancer 2004;100:851-8.
2. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3:377-84.
3. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000;85:2215-22.
4. Daniell HW. Opioid-induced androgen deficiency. Curr Opin Endocrinol Diabetes 2006;13:262-6.
5. Giri M, Kaufman JM. Opioidergic modulation of in vitro pulsatile gonadotropin releasing hormone release from the isolated medial basal hypothalamus of the male guinea pig. Endocrinology 1994;135:2137-43.
6. Blank MS, Fabbri A, Catt KJ, Dufau ML. Inhibition of luteinizing hormone release by morphine and endogenous opiates in cultured pituitary cells. Endocrinology 1986;118:2097-101.
7. Adams ML, Sewing B, Forman JB, Meyer ER, Cicero TJ. Opioid-induced suppression of rat testicular function. J Pharmacol Exp Ther 1993;266:323-8.
8. Roantree E, Zylicz Z. Opioid-induced hypogonadism in palliative care. Does it matter? Report on four patients treated with hormone substitution. Adv Pall Med 2009;8(2):69-74.
9. Craft RM, Mogil JS, Aloisi AM. Sex differences in pain and analgesia: the role of gonadal hormones. Eur J Pain 2004;8:397-411.
10. Katz N, Mazer NA. The Impact of opioids on the endocrine system. Clin J Pain 2009;25:170-5.
11. Ensrud KE, Blackwell T, Mangione CM, Bowman PJ, Bauer DC, Schwartz A, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003;163(8):949-57.
12. Kinjo M,Setoguchi S,Schneeweiss S,Solomon DH.Bone mineral density in subjects using central nervous system- active medications. Am J Med 2005;118(12):1414.
13. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med 2006;260(1):76-87.
14. Tennant F. A 10-year evaluation of chronic pain patients treated with opioids. Heroin Addict Relat Clin Probl 2009;11(1):31-4.
15. Perez-Castrillon JL, Olmos JM, Gomes JJ, Barrallo A, Riancho JA, Perera L, et al. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology 2000;72:187-94.
16. Rico H, Costales C, Cabranes JA, Escudero M. Lower serum osteocalcin levels in pregnant drug users and their newborns at the time of delivery. Obstet Gynecol 1990;75:998-1000.
17. Daniell HW. Opioid osteoporosis. Arch Intern Med 2004;164(3):338.
18. Page GG. Acute pain and immune impairment. Pain: Clin Updates 2005;XIII(1).
19. Wei G, Moss J, Yuan CS. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? Biochem Pharmacol 2003;65:1761-6.
20. Li Y, Merrill JD, Mooney K, Song L, Wang X, Guo C, et al. Morphine enhances HIV infection of neonatal macrophages. Pediatr Res 2003;54(2):282-8.
21. Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 2000;90(6):1411-4.
22. Welters ID. Is immunomodulation by opioid drugs of clinical relevance? Curr Opin Anaesthesiol 2003;16:509-13.
23. Budd K. Pain management: is opioid immunosuppression a clinical problem? Biomed Pharmacother 2006;60:310-7.
24. Weber RJ, Gomez-Flores R, Sora I, Uhl GR. Loss of morphine-induced suppression of NK cell activity and T-cell functions in m receptor knockout mice. Am J Immunol 2006;2(2):35-9.
25. McCracken LM, Iverson GL. Predicting complaints of impaired cognitive functioning in patients with chronic pain. J Pain Symptom Manage 2001;21:392-6.
26. Sjogren P, Christrup LL, Petersen MA, Hojsted J. Neuropsychological assessment of chronic non-malignant pain patients treated in a multidisciplinary pain centre. Eur J Pain 2005;9(4):453-62.
27. Kreitler S, Niv D. Cognitive impairment in chronic pain. Pain: Clin Updates 2007;XV(4 (July)).
28. Folstein MF, Folstein SE, McHugh PR. "Mini-MentalState" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
29. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39 (1):13-6.
30. Banning A, Sjogren P. Cerebral effects of long-term oral opioids in cancer patients measured by continuous reaction time. Clin J Pain 1990;6(2):91-5.
31. Sjogren P, Thomsen AB, Olsen AK. Impaired neuropsychological performance in chronic nonmalignant pain patients receiving long-term oral opioid therapy. J Pain Symptom Manage 2000;19(2):100-8.
32. Kamboj SK, Tookman A, Jones L, Curran HV. The effects of immediate-release morphine on cognitive functioning in patients receiving chronic opioid therapy in palliative care. Pain 2005;117(3):388-95.
33. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349 (20):1943-53.
34. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical Issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125: 172-9.
35. Angst MS, Clark JD. Opioid induced hyperalgesia. Anesthesiology 2006;104: 570-87.
36. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994;14:2301-12.
37. + currents. J Neurosci Res 1995;42:493-503.
38. Li X, Angst MS, Clark JD. A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res 2001;86:56-62.
39. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Scientific World J 2007;7:98-111.
40. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30.